Regeneron Pharmaceuticals (LTS:0R2M) Change In Receivables : $-554 Mil (TTM As of Dec. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Regeneron Pharmaceuticals Change In Receivables?

Regeneron Pharmaceuticals's change in receivables for the quarter that ended in Dec. 2024 was $-118 Mil. It means Regeneron Pharmaceuticals's Accounts Receivable increased by $118 Mil from Sep. 2024 to Dec. 2024 .

Regeneron Pharmaceuticals's change in receivables for the fiscal year that ended in Dec. 2024 was $-554 Mil. It means Regeneron Pharmaceuticals's Accounts Receivable increased by $554 Mil from Dec. 2023 to Dec. 2024 .

Regeneron Pharmaceuticals's Accounts Receivable for the quarter that ended in Dec. 2024 was $6,212 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Regeneron Pharmaceuticals's Days Sales Outstanding for the three months ended in Dec. 2024 was 149.59.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Regeneron Pharmaceuticals's liquidation value for the three months ended in Dec. 2024 was $6,809 Mil.

Regeneron Pharmaceuticals Change In Receivables Historical Data

The historical data trend for Regeneron Pharmaceuticals's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regeneron Pharmaceuticals Change In Receivables Chart

Regeneron Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Receivables

Get a 7-Day Free Trial

-1,356.10

-1,927.40

707.80

-338.80

-554.00

Regeneron Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Change In Receivables	Get a 7-Day Free Trial															-82.70	446.80	-494.10	-388.90	-117.80

Regeneron Pharmaceuticals Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-554 Mil.

Regeneron Pharmaceuticals (LTS:0R2M) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Regeneron Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	6211.9	/	3789.2	*	91
=	149.59

2. In Ben Graham's calculation of liquidation value, Regeneron Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

Regeneron Pharmaceuticals's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	9012.5	-	8405.8	+	0.75 * 6211.9	+	0.5 * 3087.3
=	6,809

Regeneron Pharmaceuticals Change In Receivables Related Terms

Thank you for viewing the detailed overview of Regeneron Pharmaceuticals's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Regeneron Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (LTS:0R2M) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

REGN:USA REGN:Mexico RGO:Germany RGO:Germany REGN34:Brazil REGN:Austria

Address

777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707

Website

https://www.regeneron.com

Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Regeneron Pharmaceuticals Headlines

No Headlines